Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime

Jiajun Liu, Michael Neely, Jeffrey Lipman, Fekade Sime, Jason A. Roberts, Patrick J. Kiel, Sean N. Avedissian, Nathaniel J. Rhodes, Marc H. Scheetz

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background and Objective: Understanding pharmacokinetic disposition of cefepime, a β-lactam antibiotic, is crucial for developing regimens to achieve optimal exposure and improved clinical outcomes. This study sought to develop and evaluate a unified population pharmacokinetic model in both pediatric and adult patients receiving cefepime treatment. Methods: Multiple physiologically relevant models were fit to pediatric and adult subject data. To evaluate the final model performance, a withheld group of 12 pediatric patients and two separate adult populations were assessed. Results: Seventy subjects with a total of 604 cefepime concentrations were included in this study. All adults (n = 34) on average weighed 82.7 kg and displayed a mean creatinine clearance of 106.7 mL/min. All pediatric subjects (n = 36) had mean weight and creatinine clearance of 16.0 kg and 195.6 mL/min, respectively. A covariate-adjusted two-compartment model described the observed concentrations well (population model R2, 87.0%; Bayesian model R2, 96.5%). In the evaluation subsets, the model performed similarly well (population R2, 84.0%; Bayesian R2, 90.2%). Conclusion: The identified model serves well for population dosing and as a Bayesian prior for precision dosing.

Original languageEnglish (US)
Pages (from-to)1027-1036
Number of pages10
JournalClinical Pharmacokinetics
Volume59
Issue number8
DOIs
StatePublished - Aug 1 2020

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime'. Together they form a unique fingerprint.

Cite this